A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study

International Journal of Cardiology

Volumn 162, Issue 2, 2013, Pages 112-116

  Pfister, Roman ^a   Cairns, Richard ^b   Erdmann, Erland ^a   Schneider, Christian A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Isaac Newton Centre   (United Kingdom)

Author keywords

Diabetes mellitus; Heart failure; Pioglitazone; Risk score

Indexed keywords

DIURETIC AGENT; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG USE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; MULTICENTER STUDY; PREDICTION;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 84870717966     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.05.056     Document Type: Article

References (30)

1. J.M. Arnold, S. Yusuf, and J. Young Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation 107 2003 1284 1290
2. G.A. Nichols, C.M. Gullion, C.E. Koro, S.A. Ephross, and J.B. Brown The incidence of congestive heart failure in type 2 diabetes: an update Diab Care 27 2004 1879 1884
3. A.G. Bertoni, W.G. Hundley, M.W. Massing, D.E. Bonds, G.L. Burke, and D.C. Goff Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes Diab Care 27 2004 699 703
4. J. Butler, A. Kalogeropoulos, and V. Georgiopoulou Incident heart failure prediction in the elderly: the health ABC heart failure score Circ Heart Fail 1 2008 125 133
5. W.B. Kannel, R.B. D'Agostino, H. Silbershatz, A.J. Belanger, P.W. Wilson, and D. Levy Profile for estimating risk of heart failure Arch Intern Med 159 1999 1197 1204
6. G.A. Nichols, T.A. Hillier, J.R. Erbey, and J.B. Brown Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors Diab Care 24 2001 1614 1619
7. M. Komajda, J.J. McMurray, and H. Beck-Nielsen Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial Eur Heart J 31 2010 824 831
8. A.A. Carr, P.R. Kowey, and R.B. Devereux Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies Am J Cardiol 96 2005 1530 1536
9. L. Vaur, P. Gueret, M. Lievre, S. Chabaud, and P. Passa Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study Diab Care 26 2003 855 860
10. I.M. Stratton, A.I. Adler, and H.A. Neil Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
11. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
12. B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diab Care 27 2004 1647 1653
13. E. Erdmann, B. Charbonnel, and R.G. Wilcox Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08) Diab Care 30 2007 2773 2778
14. P.M. Rautaharju, B. Surawicz, and L.S. Gettes AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology Circulation 119 2009 e241 e250
15. B. Surawicz, R. Childers, and B.J. Deal AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology J Am Coll Cardiol 53 2009 976 981
16. A. Sagie, M.G. Larson, R.J. Goldberg, J.R. Bengtson, and D. Levy An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) Am J Cardiol 70 1992 797 801
17. W. Sauerbrei, P. Royston, and H. Binder Selection of important variables and determination of functional form for continuous predictors in multivariable model building Stat Med 26 2007 5512 5528
18. D. Hosmer, and S. Lemeshow Applied survival analysis 1999 John Wiley & Sons New York
19. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
20. J.H. Jeong, J.H. Kim, and Y.H. Park Incidence of and risk factors for bundle branch block in adults older than 40 years Korean J Intern Med 19 2004 171 178
21. N.F. Murphy, C.R. Simpson, and F.A. McAlister National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland Heart 90 2004 1129 1136
22. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors N Engl J Med 327 1992 685 691
23. H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
24. K.B. Filion, L. Joseph, J.F. Boivin, S. Suissa, and J.M. Brophy Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis Pharmacoepidemiol Drug Saf 18 2009 973 976
25. S. Kaul, A.F. Bolger, D. Herrington, R.P. Giugliano, and R.H. Eckel Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation J Am Coll Cardiol 55 2010 1885 1894
26. H.J. Dargie, P.R. Hildebrandt, and G.A. Riegger A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure J Am Coll Cardiol 49 2007 1696 1704
27. L. Ryden, I. Thrainsdottir, and K. Swedberg Adjudication of serious heart failure in patients from PROactive Lancet 369 2007 189 190
28. I. Thrainsdottir, E. Erdmann, L. Ryden, and R. Spanheimer Adjudication of serious heart failure in patients with type 2 diabetes and cardiovascular disease: results from PROactive Circulation 114 2006 II-849-
29. V.L. Roger, S.A. Weston, and M.M. Redfield Trends in heart failure incidence and survival in a community-based population JAMA 292 2004 344 350
30. A.D. Struthers, and A.D. Morris Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths Lancet 359 2002 1430 1432